GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30,p= 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44,p= 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.
GIM 13-AMBRA是一项纵向队列研究，旨在描述939例HER2阴性转移性乳腺癌患者的治疗策略及相关预后指标。在Luminal型（30.2%）和三阴性乳腺癌（33.3%）患者中，以紫杉类药物为基础的方案或紫杉类联合靶向药物（主要为贝伐珠单抗）是首选治疗方案。中位无进展生存期1为12.5个月（95% CI 16.79-19.64），各亚型间无显著差异；而三阴性乳腺癌患者的中位首次治疗变更时间（7.7个月，95% CI 5.7-9.2）显著短于Luminal A型（13.2个月，95% CI 11.7-15.1）和Luminal B型患者（11.8个月，95% CI 10.3-12.8）。三阴性乳腺癌患者的无进展生存期2显著更短（5.5个月，95% CI 4.3-6.5；Luminal A型为9.4个月，95% CI 8.1-10.7；Luminal B型为7.7个月，95% CI 6.8-8.2；F值4.30，p=0.014）。三阴性乳腺癌患者的二次治疗变更时间也显著低于其他两种亚型。Luminal A型患者的中位总生存期1为35.2个月（95% CI 30.8-37.4），显著高于Luminal B型（28.9个月，95% CI 26.2-31.2）和三阴性乳腺癌患者（18.5个月，95% CI 16-20.1，F值7.44，p=0.0006）。GIM 13-AMBRA研究是意大利迄今发表的最大规模研究之一，为HER2阴性转移性乳腺癌患者一线、二线及后续治疗的时间结局提供了重要参考依据。
肿瘤(癌症)患者之家